Literature DB >> 1672968

Circulating Epstein-Barr virus-carrying B cells in acute malaria.

K M Lam1, N Syed, H Whittle, D H Crawford.   

Abstract

Epstein-Barr virus (EBV) infection and Plasmodium falciparum malaria are two known cofactors in the aetiology of endemic Burkitt's lymphoma. To assess the relation between these factors, limiting dilution analysis was used to assess the number of EBV-carrying B cells in the circulation of Gambian children during and after acute malaria. Numbers of virus-carrying cells were five times higher in acute malaria patients and in UK patients with infectious mononucleosis than in convalescent malaria patients and in healthy control adults from the UK. Spontaneous outgrowth in limiting dilution cultures from acute malaria samples was inhibited by acyclovir, a viral DNA polymerase inhibitor. The mechanism of outgrowth, therefore, was virus release from the in-vivo infected cell, which led to infection and immortalisation of co-cultured normal B cells. The findings provide evidence that acute malaria is associated with an increase in the number of EBV-carrying B cells in the circulation. Because of this increase, there is a greater chance of a cytogenetic abnormality occurring in such a cell, with consequent evolution of Burkitt's lymphoma.

Entities:  

Mesh:

Year:  1991        PMID: 1672968     DOI: 10.1016/0140-6736(91)90203-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  39 in total

Review 1.  Immune regulation of Epstein-Barr virus (EBV): EBV nuclear antigen as a target for EBV-specific T cell lysis.

Authors:  D J Moss; I S Misko; T B Sculley; A Apolloni; R Khanna; S R Burrows
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1.

Authors:  Barbara Adler; Eveline Schaadt; Bettina Kempkes; Ursula Zimber-Strobl; Barbara Baier; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 3.  The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma.

Authors:  Ann M Moormann; Cynthia J Snider; Kiprotich Chelimo
Journal:  Curr Opin Infect Dis       Date:  2011-10       Impact factor: 4.915

Review 4.  Molecular virology of Epstein-Barr virus.

Authors:  G W Bornkamm; W Hammerschmidt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

5.  Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice.

Authors:  R G Caldwell; R C Brown; R Longnecker
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Plasmodium falciparum infection is associated with Epstein-Barr virus reactivation in pregnant women living in malaria holoendemic area of Western Kenya.

Authors:  Ibrahim I Daud; Sidney Ogolla; Asito S Amolo; Eunice Namuyenga; Kenneth Simbiri; Elizabeth A Bukusi; Zipporah W Ng'ang'a; Robert Ploutz-Snyder; Peter O Sumba; Arlene Dent; Rosemary Rochford
Journal:  Matern Child Health J       Date:  2015-03

Review 7.  The Epstein-Barr virus and its association with human cancers.

Authors:  K R Baumforth; L S Young; K J Flavell; C Constandinou; P G Murray
Journal:  Mol Pathol       Date:  1999-12

Review 8.  Biology and disease associations of Epstein-Barr virus.

Authors:  D H Crawford
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

Review 9.  Epstein-Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects.

Authors:  V Schuster; H W Kreth
Journal:  Eur J Pediatr       Date:  1992-10       Impact factor: 3.183

10.  Murine AIDS protects mice against experimental cerebral malaria: down-regulation by interleukin 10 of a T-helper type 1 CD4+ cell-mediated pathology.

Authors:  M Eckwalanga; M Marussig; M D Tavares; J C Bouanga; E Hulier; J H Pavlovitch; P Minoprio; D Portnoï; L Rénia; D Mazier
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.